- |||||||||| Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Clinical, Journal: Early Experience and Effectiveness of Long-Acting Injectable Cabotegravir and Rilpivirine in a South Side Chicago HIV Clinic. (Pubmed Central) - Mar 12, 2025
In a pharmacy-led model, 118 (18%) people with HIV were referred and 78 (12%) initiated long-acting injectable cabotegravir/rilpivirine from 1 January 2021 to 31 May 2023. Implementation, especially for people with HIV who were not virally suppressed, requires further support for patients, providers, and clinic systems.
- |||||||||| Observational data, Journal: Change in weight and BMI associated with switching to bictegravir/emtricitabine/tenofovir alafenamide versus a dolutegravir-based regimen among virologically suppressed adults living with HIV through 144 weeks. (Pubmed Central) - Mar 12, 2025
This observational study collected demographics, clinical characteristics, weight, and BMI from virologically suppressed adults switched to BIC/emtricitabine/tenofovir alafenamide (TAF), emtricitabine/TAF plus DTG, DTG/abacavir/lamivudine, DTG/rilpivirine (RPV), and DTG/lamivudine 2 years prior to switch through 144 weeks post-switch...DTG plus emtricitabine/TAF switches had the highest annualized weight gain (0.68?kg/year, 95% confidence interval: -0.32, 1.65) whereas, DTG/RPV switches had the lowest annualized weight gain (-2.22?kg/year, 95% confidence interval: -3.69, -0.62) post-switch...Baseline BMI?<?18.5?kg/m2 was associated with the highest annualized weight gain post-switch, whereas switching from protease inhibitors and self-report of dieting were associated with the lowest annualized weight gain post-switch. At week 144, switching to a BIC versus DBR were both associated with lower annualized weight gain post-switch among a large and diverse cohort of treatment-experienced people living with HIV.
- |||||||||| In Vitro Modulation of Adipocyte Differentiation by TAF/TDF After Challenge With New ARV Regimens (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_1371;
Background We previously demonstrated in a 3T3L1cells in vitro model of adipogenesis, that Integrase Strand Transfer Inhibitors (INSTI) increase adipogenesis, while, tenofovir alafenamide fumarate (TAF) and tenofovir disoproxil fumarate (TDF), displayed an inhibitory effect, counteracting increased adipogenesis caused by INSTIs [dolutegravir (DTG), bictegravir (BIC)]...Methods We used a 3T3-L1 cells in vitro model of adipogenesis to study the effects on adipocyte differentiation of the NNRTIs doravirine (DOR) and rilpivirine (RPV), alone or in combination with the previously evaluated DTG and the newer INSTI cabotegravir (CAB), or TDF or TAF...Furthermore, NNRTIs and CAB enhanced the expression levels of ER-TR7 compared to control, being the combination DTG+DOR less effective in this activity. Conclusions Our data support the evidence that in-vitro challenge of 3T3-L1 cells with INSTIs and NNRTIs is able to increase adipocytic differentiation and to drive a number of these cells toward the expression of fibroblastic features, whereas TAF and TDF when combined to different ARV have an antagonistic role on this phenomenon confirming our previous report.
- |||||||||| Edurant (rilpivirine) / J&J, Isentress (raltegravir) / Merck (MSD)
Molecular Epidemiology of HIV-1 Transmitted Drug Resistance Among Subtypes Circulating in Italy (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_914;
However, the impact of the detected TDR on the susceptibility to currently recommended first-line regimens is negligible. NGS genotyping can improve the characterization of transmission networks of resistance, allowing the detection of TC harbouring minority-resistant species not detectable with Sanger.
- |||||||||| Edurant (rilpivirine) / J&J
Rilpivirine Drug-Resistant Mutations in Experienced Patients in Mexico: Impact on Long-Acting ART (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_912;
Conclusions This retrospective analysis indicates that rilpivirine DRMs are common in a setting wherein NNRTI-based treatment was widely implemented, and has implications for operational implementation of CAB/RPV LA. Screening for existing DRMs is logistically and technically challenging in Mexico and could be a barrier to use of CAB/RPV LA.
- |||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Edurant (rilpivirine) / J&J, Pifeltro (doravirine) / Merck (MSD)
HIV-1 Drug Resistance Trends in the Era of Modern Antiretrovirals: 2018-2024 (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_911;
Doravirine and rilpivirine DRMs remained low, with respective 2024 prevalences of 2% (RNA) and 2.9% (DNA) and 6.3% (RNA) and 10.1% (DNA)...Cabotegravir DRM prevalence in 2024 was 3.8% (RNA) and 2.5% (DNA)...Conclusions Prevalence of NRTI and NNRTI resistance declined which is consistent with increased use of regimens with higher resistance barriers, improved tolerability, and more convenient dosing, resulting in better adherence. Prevalence of INSTI DRMs was low, supporting US guidelines for limiting INSTI resistance testing to cases of treatment failure, suspected transmitted resistance, or infection during INSTI-based PrEP.
- |||||||||| ART Exposure and Accelerated Aging in PLHIV: Insights From Proteomic and Methylation Clocks (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_605;
P
In contrast, longer exposure to tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), darunavir (DRV), atazanavir (ATV), and dideoxynucleoside analogues (d-drugs) was related to higher age advancement scores (Figure 1; P<0.05, adjusted for chronological age)...Conclusions Cumulative ART exposure influences age acceleration in PLHIV, with distinct effects across regimens and drug classes. Innate immune pathways appear to be key drivers of these effects and are promising therapeutic targets to mitigate accelerated aging.
- |||||||||| Edurant (rilpivirine) / J&J, Pifeltro (doravirine) / Merck (MSD), Tivicay (dolutegravir) / ViiV Healthcare
Dolutegravir With Either Doravirine or Rilpivirine: Two-Drug Antiretroviral Therapy Outcomes (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_526;
Conclusions Observed differences in VS following switch to DRG+RPV and DTG+DOR may be due to differences in participant characteristics, adherence, viral resistance patterns, and the dual regimens. Further studies are needed to evaluate efficacy of dual NRTI-free regimens in real-world settings.
- |||||||||| Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
PK/PD data, Journal: The steady-state pharmacokinetics of fixed-dose combination dolutegravir+rilpivirine in hemodialysis. (Pubmed Central) - Feb 26, 2025
Exposures throughout the dosing interval were greater than the reported protein-binding-adjusted IC90 efficacy values for DTG (64?ng/ml) and RPV (12?ng/ml) in all participants. These data suggest no dosing modifications are needed for the FDC DTG+RPV regimen in hemodialysis.
- |||||||||| Apretude (cabotegravir extended-release injectable suspension) / ViiV Healthcare, Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Willingness to Switch to Long-Acting Injectable Cabotegravir and Rilpivirine Every 2 Months for People Living with HIV in Nanjing, China. (Pubmed Central) - Feb 10, 2025
Our survey demonstrated that the majority of PLWH were willing to switch to CAB+RPV therapy, mainly due to its improved convenience and reduced risk of disease exposure. However, their concerns regarding price, efficacy, and safety could be the key challenges for the clinical implementation of the CAB+RPV LA regimen in the future.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
P3 data, Journal, Patient reported outcomes: Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir?+?Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study. (Pubmed Central) - Jan 17, 2025
P3
Most (90%, 382/425) questionnaire respondents preferred CAB?+?RPV LA vs. BIC/FTC/TAF (5%, 21/425). Switching to CAB?+?RPV LA was associated with significantly improved treatment satisfaction and relief from the fear of disclosure, anxiety surrounding adherence and reminder of HIV status.
- |||||||||| Preclinical, Journal: Repurposing Non-Nucleosidic Reverse Transcriptase Inhibitors (NNRTIs) to Overcome EGFR T790M-Mediated Acquired Resistance in Non-Small Cell Lung Cancer. (Pubmed Central) - Jan 14, 2025
Using in silico molecular docking, Rilpivirine demonstrated a docking score of -7.534?kcal/mol, comparable to established epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) like Osimertinib and WZ4002...Enzymatic assays revealed that Rilpivirine inhibited the double mutant epidermal growth factor receptor tyrosine kinase (EGFR TK) with an IC50 value of 54.22?nM and spared the wild-type EGFR TK with an IC50 of 22.52?nM. These findings suggest Rilpivirine's potential as a therapeutic agent for NSCLC with EGFR L858R/T790M mutations.
- |||||||||| Apretude (cabotegravir extended-release injectable suspension) / ViiV Healthcare, Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Cabotegravir and rilpivirine long acting injectables in a pregnant woman living with HIV. (Pubmed Central) - Dec 17, 2024
Despite placental transfer, no congenital malformations were noted. Bimonthly CAB/RPV LAI may not be suitable for pregnant women and monitoring of exposed infants is warranted.
- |||||||||| Enrollment change, Trial completion date, Trial primary completion date: Characterization of Acute and Recent HIV-1 Infections in Zurich. (clinicaltrials.gov) - Dec 11, 2024
P=N/A, N=800, Recruiting,
Bimonthly CAB/RPV LAI may not be suitable for pregnant women and monitoring of exposed infants is warranted. N=2017 --> 800 | Trial completion date: Jan 2025 --> Dec 2028 | Trial primary completion date: Jan 2025 --> Dec 2028
- |||||||||| Edurant (rilpivirine) / J&J, Intelence (etravirine) / J&J
Review, Journal: Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors (2019-2023). (Pubmed Central) - Nov 23, 2024
Moreover, developing new DAPY analogues with broad-spectrum antiviral activity has become a key research priority. This review provides a comprehensive overview of the evolution of DAPYs from 2019 to 2023, including scaffold hopping and structural modifications of the right wing, left wing, central pyrimidine core, and linker, affording valuable insights for the future development of effective HIV-1 inhibitors.
- |||||||||| Antiretroviral therapy in pregnancy in England in 2019?2022: common regimens and treatment modifications () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_130;
Among pregnancies conceived on ART, most common (reported in >5%) first regimens were efavirenz (EFV) + tenofovir disoproxil fumarate (TDF) + emtricitabine (FTC) (13.5% [267/1974]), rilpivirine (RPV) +TDF+FTC (11.6% [228/1974]), darunavir/ritonavir (DRV/r) +TDF+FTC (8.0% [158/1974]), dolutegravir (DTG) + lamivudine (3TC) + abacavir (ABC) (7.7% [152/1974]), and raltegravir (RAL) +TDF+FTC (6.4% [127/1974]). Where ART was initiated during pregnancy (55.7% [234/420] diagnosed antenatally), median gestational age at start was 15 weeks (IQR 12
- |||||||||| efavirenz / Generic mfg.
Journal: The effect of efavirenz on reward processing in asymptomatic people living with HIV: a randomized controlled trial. (Pubmed Central) - Oct 8, 2024
In this multicenter randomized controlled trial, asymptomatic adult participants stable on emtricitabine/tenofovirdisoproxil fumarate (FTC/TDF)/EFV were randomly assigned in a 2:1 ratio to switch to FTC/TDF/rilpivirine (RPV) (n?=?30) or continue taking FTC/TDF/EFV (n?=?13)...At the behavioral level, both groups had faster response times and better response accuracy during rewarding versus nonrewarding trials, with no improvement resulting from switching FTC/TDF/EFV to FTC/TDF/RPV...It is therefore likely that EFV does not affect motivational control. Further research is needed to determine whether EFV affects motivational control in HIV populations with different characteristics.
- |||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal, Real-world evidence, Real-world: Process evaluation and early outcomes of real-world implementation of a pharmacist-driven cabotegravir/rilpivirine long-acting injectable initiative. (Pubmed Central) - Sep 26, 2024
Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
- |||||||||| Aptivus (tipranavir) / Boehringer Ingelheim, Edurant (rilpivirine) / J&J, Viracept (nelfinavir) / ViiV Healthcare, Roche
Journal: Pretreatment drug resistance among people living with HIV from 2018 to 2022 in Guangzhou, China. (Pubmed Central) - Sep 26, 2024
Among PI, resistance to tipranavir (0.8%), nelfinavir (0.6%), fosamprenavir (0.2%) and lopinavir (0.1%) was most frequent...The overall prevalence of PDR in Guangzhou was moderate, with relatively severe NNRTI resistance. Therefore, it remains crucial to continue monitoring PDR among newly diagnosed HIV-infected individuals.
- |||||||||| Review, Journal: Current status of the small molecule anti-HIV drugs in the pipeline or recently approved. (Pubmed Central) - Aug 22, 2024
There is a considerable progress in the development of new anti-HIV drugs and the effort will continue since HIV infections has no cure or vaccine till now. Efforts are needed to reduce the toxicity of available drugs or discover new drugs with new classes which can delay the development of resistance.
- |||||||||| Prezista (darunavir) / J&J, Edurant (rilpivirine) / J&J, Dovato (dolutegravir/lamivudine) / ViiV Healthcare
Is the U=U status maintained after switching to a dual regimen? The answer from the Icona cohort Study (Limatambo 2/Channel 2) - Aug 9, 2024 - Abstract #HIVR4P2024HIVR4P_61;
We included PWH in the ICONA cohort who had reached a U=U status as of January 2014 while on triple therapy and were subsequently switched to dolutegravir(DTG)+lamivudine(3TC), DTG+rilpivirine(RPV) or darunavir/boosted(DRV/b)+3TC therapy. Our findings confirm a low risk of losing U=U after switching to 2DR, regardless of the type of therapy used.
|
